Today: 3 April 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

Scholar Rock shares fell 3.2% to $43.76 Tuesday afternoon, underperforming biotech peers as investors watched for updates on FDA reinspection timing for its lead drug, apitegromab. The company aims to resubmit its biologics license application in 2026 after the Indiana fill-finish site, now owned by Novo Nordisk, completes remediation and is reinspected by year-end 2025.
30 December 2025
·
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions shares dropped 3.5% to $10.02 in thin year-end trading Tuesday, underperforming a steady U.S. market. The decline followed Federal Reserve minutes showing policy divisions and came as investors awaited January jobs and inflation data. Trading volume in TIC lagged its recent average, and peers Mistras Group and Jacobs Solutions slipped less than 1%.
30 December 2025
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries shares fell 3.9% to $8.90 Tuesday after early gains, trading between $8.90 and $9.39. The drop followed news that CEO Lewis Black met U.S. officials and signed a deal tied to future tungsten supply from the Sangdong mine in South Korea, which is set to start production in early 2026. Almonty recently raised $129.4 million in a U.S. share sale and delivered its first ore to Sangdong’s staging area.
30 December 2025
···
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Caris Life Sciences shares fell 1.8% to $27.44 by 2:41 p.m. ET Tuesday, underperforming biotech peers as sector benchmarks declined. The drop followed recent attention on Caris’ Genentech partnership, which includes $25 million upfront and up to $1.1 billion in potential milestones. The S&P 500 and Nasdaq were flat. Investors are watching Caris’ test volumes and revenue guidance.
30 December 2025
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management shares dropped 3.1% to $163.85 Tuesday afternoon, underperforming rivals as fresh Federal Reserve minutes showed policymakers split on future rate cuts. A Reuters column noted shrinking yield premiums in private credit, a core Ares business, as public markets regain ground. About 966,000 Ares shares traded, with the stock hitting a low of $163.49. Blackstone was flat; Apollo, KKR, and Carlyle edged down less than 1%.
30 December 2025
··
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Karman Holdings shares fell 3.6% to $74.81 in New York afternoon trading Tuesday, underperforming the broader market after a $258.7 million outflow from the SPDR S&P Aerospace & Defense ETF. The stock touched a session low of $74.21, with about 465,000 shares traded. Investors are watching for signs of stabilization ahead of the company’s next quarterly update.
30 December 2025
··
1 … 336 337 338 339 340 … 584

Stock Market Today

  • Oil Prices Surge and Stocks End Week Mixed After Trump's Iran Address
    April 3, 2026, 7:32 AM EDT. Oil prices surged over 11% after President Trump's national address signaled continued U.S. attacks on Iran without a clear end timeline, pushing U.S. crude above $111 per barrel. This spike, amid restricted shipping in the Strait of Hormuz where a fifth of global oil transits, caused early stock market losses. Despite this, the S&P 500 managed a modest 0.1% gain to 6,582.69, marking its first weekly rise since the Iran conflict began, up 3.4% for the week. The Dow Jones Industrial Average fell 61 points, or 0.1%, to 46,504.67, while the Nasdaq rose 0.2% to 21,879.18. Markets will close Friday for Good Friday. Elevated crude prices remain a key driver of volatile global stock movements.
Go toTop